Prudential Financial Inc Novavax Inc Transaction History

Prudential Financial Inc

$70 Billion
Q3 2024

A detailed history of Prudential Financial Inc transactions in Novavax Inc stock. As of the latest transaction made, Prudential Financial Inc holds 10,463 shares of NVAX stock, worth $75,542. This represents 0.0% of its overall portfolio holdings.

Number of Shares

10,463

Previous 10,528 0.62%

Holding current value

$75,542

Previous $133,000 0.75%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$10.71 - $17.11 $696 - $1,112	-65 Reduced 0.62%	10,463 $132,000
Q2 2024 Aug 13, 2024	BUY	$3.89 - $20.97 $40,953 - $220,772	10,528 New	10,528 $133,000
Q2 2023 Aug 11, 2023	BUY	$6.67 - $9.52 $41,273 - $58,909	6,188 New	6,188 $45,000
Q1 2022 May 13, 2022	SELL	$69.73 - $142.9 $153,127 - $313,808	-2,196 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$134.56 - $217.97 $1.69 Million - $2.73 Million	-12,542 Reduced 85.1%	2,196 $394,000
Q3 2021 Nov 15, 2021	BUY	$177.8 - $270.58 $221,183 - $336,601	1,244 Added 9.22%	14,738 $3.13 Million
Q2 2021 Aug 16, 2021	SELL	$121.0 - $257.67 $1.79 Million - $3.81 Million	-14,803 Reduced 52.31%	13,494 $2.87 Million
Q1 2021 May 12, 2021	BUY	$112.98 - $319.93 $186,304 - $527,564	1,649 Added 6.19%	28,297 $5.13 Million
Q4 2020 Feb 16, 2021	BUY	$78.74 - $139.5 $2.08 Million - $3.69 Million	26,439 Added 12650.24%	26,648 $2.97 Million
Q3 2020 Aug 05, 2021	SELL	$79.44 - $178.51 $1.66 Million - $3.74 Million	-20,949 Reduced 99.01%	209 $23,000
Q3 2020 Nov 16, 2020	BUY	$79.44 - $178.51 $1.3 Million - $2.92 Million	16,330 Added 338.24%	21,158 $2.29 Million
Q2 2020 Aug 12, 2020	BUY	$13.86 - $83.61 $66,916 - $403,669	4,828 New	4,828 $402,000

Others Institutions Holding NVAX

# of Institutions

289

Shares Held

93.1M

Call Options Held

5.88M

Put Options Held

6.7M

View Full List

About NOVAVAX INC

Ticker NVAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,215,104
Market Cap $565M
Description
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...

More about NVAX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Prudential Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Prudential Financial Inc with notifications on news.

Account

Prudential Financial Inc Novavax Inc Transaction History